

# A randomised controlled trial to study the side effect profile and to establish measures of efficacy using photofrin or 5-aminolaevulinic acid (ALA) photodynamic therapy in the eradication of dysplasia in Barretts columnar lined oesophagus

<b>Submission date</b> 26/01/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 07/02/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 28/08/2013	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Laurence Lovat

**Contact details**  
National Medical Laser Centre  
Charles Bell House  
67-73 Riding House Street  
London  
United Kingdom  
W1W 7EJ  
med.laser@ucl.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

Version 3.1

## **Study information**

**Scientific Title**

**Study objectives**

To determine whether photodynamic therapy for high grade dysplasia in Barrett's oesophagus using aminolaevulinic acid has less side effects than photofrin. To develop novel measures of efficacy.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Berkshire Research Ethics Committee, 13/01/2006, ref: 05/Q1602/193

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Treatment

**Participant information sheet**

**Health condition(s) or problem(s) studied**

High grade dysplasia in Barrett's oesophagus

**Interventions**

Photodynamic therapy using 5-aminolaevulinic acid versus photofrin

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Aminolaevulinic Photofrin

**Primary outcome measure**

1. Eradication of high grade dysplasia
2. Prevention of oesophageal cancer
3. Side effect profiles of different types of photodynamic therapy

**Secondary outcome measures**

1. Quality of life outcomes
2. Develop novel methods for treatment efficacy
3. Reversal of Barrett's oesophagus

**Overall study start date**

01/02/2006

**Completion date**

01/02/2009

## **Eligibility**

**Key inclusion criteria**

1. Patients with high grade dysplasia in Barrett's oesophagus but without invasive cancer
2. Aged over 21

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

66

**Key exclusion criteria**

1. Severe cardiovascular disease
2. Liver cirrhosis or seriously impaired hepatic or renal function
3. Depot antipsychotics
4. Concomitant chemoradiotherapy
5. Pregnancy
6. Porphyria
7. Previous photodynamic therapy

**Date of first enrolment**

01/02/2006

**Date of final enrolment**

01/02/2009

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**National Medical Laser Centre**

London

United Kingdom

W1W 7EJ

## Sponsor information

**Organisation**

University College London (UK)

**Sponsor details**

Gower street

London

England

United Kingdom

WC1E 6BT

**Sponsor type**

University/education

**ROR**

<https://ror.org/02jx3x895>

## Funder(s)

**Funder type**

Government

**Funder Name**

National Medical Laser Centre (UK)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2013		Yes	No